Christoph Neuwirth

Also affiliated with Kantonsspital St. Gallen

MedicineNeuroscienceEngineering

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial”.

Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial

The Lancet Neurology(2024)10.1016/s1474-4422(24)00373-9

N/A

0.653DataRank · unranked

31 citations

Andreas Leha, Helen Bidner, Isabell Cordts, Johannes Dorst, René Günther +28 more

Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series

The Lancet(2025)10.1016/s0140-6736(25)00513-6

N/A

0DataRank · unranked

34 citations

Matthew B. Harms, Vladislav A. Korobeynikov, Olivia M. Rifai, Benjamin N. Hoover, Elizabeth A. Harrington +30 more